Abstract： Objective： To observe the clinical effect of Jianpi Jiedu Decoction combined with transarterial chemoembolization(TACE) for primary hepatic cancer(PHC) and its effect on quality of life. Methods：A total of 86 cases of PHC patients were divided into the treatment group and the control group according to the random number table method，with 43 cases in each group. The control group was treated with TACE， and the treatment group was additionally treated with Jianpi Jiedu Decoction based on the treatment of the control group. The clinical effects and the incidence of adverse reactions in the two groups were compared. Before and after treatment，the changes in levels of matrix metalloproteinase-2(MMP-2)， matrix metalloproteinase- 9(MMP- 9)， vascular endothelial growth factor(VEGF) and interleukin- 2(IL- 2)， and scores of quality of life were observed between the two groups. Results： The overall response rate was 51.16% in the treatment group， higher than that of 30.23% in the control group(P＜0.05). After treatment，the levels of MMP-2，MMP-9 ，VEGF and IL-2 in serum in the two groups were decreased when compared with those before treatment(P＜0.05)，the above levels in serum in the treatment group were lower than those in the control group(P＜0.05). After treatment，the scores of mental function，social relations， physiological function and material life in the two groups were increased when compared with those before treatment，and which were higher in the treatment group than those in the control group(P＜ 0.05). The incidence of adverse reactions was 4.65% in the treatment group，lower than that of 18.60% in the control group(P＜0.05). Conclusion： Jianpi Jiedu Decoction combined with TACE has a significant curative effect in treating PHC，and can effectively regulate the levels of MMP-2，MMP-9，VEGF and IL-2，improve quality of life of patients，and reduce the incidence of adverse reactions.